Traders could go long ISRG at current levels.
Stand aside and let things "shake out".
Here's why the current weakness in Bionano Genomics could be a buying opportunity.
The news sent shares of the genome editing company skyward after the stock had been basing for months.
The 2021 Tax Loss Selling Recovery Portfolio didn't do much in April but is soundly beating the market six months after inception.
Let's look over the charts and indicators.
I have a problem with stocks that trade for pennies one day and then soar higher the next.
Here's how traders can play shares of the contract research company.
If you look at the economy as between service and tech you find the old-guard being overrun.
The biopharma company's stock has built a nice base, which suggests the shares could keep moving significantly higher in the coming months.